| PANDEMIC ALERT LEVEL |
| 123456 |
| Mpox Discussion Forum: Latest News & Information Regarding the Clade 1b Mpox Virus |
On M-pox |
Post Reply 
|
Page <1 111213 |
| Author |
 Topic Search  Topic Options
|
Dutch Josh 2 
Admin Group 
Joined: 21 Aug 2024 Status: Online Points: 1783 |
 Post Options
 Thanks(0)
 Quote Reply
 Posted: 09 Feb 2025 at 12:26am |
|
DJ-I will mix Mpox news in "new pandemic item" more often...
< aria-label="Grok s" role="" ="-175oi2r r-1777fci r-bt1l66 r-bztko3 r-lrvibr r-1loqt21 r-1ny4l3l" ="" style="text-align: inherit; font-size: inherit; font-family: inherit; align-items: stretch; border-width: 0px; border-style: solid; border-color: black; display: flex; flex-basis: auto; flex-direction: column; flex-shrink: 0; list-style: none; margin: 0px; min-height: 20px; min-width: 0px; padding: 0px; : relative; : 0; overflow: ; justify-: center; cursor: pointer; outline-style: none; user-: none;"> < aria-expanded="false" aria-haspopup="menu" aria-label="More" role="" ="-175oi2r r-1777fci r-bt1l66 r-bztko3 r-lrvibr r-1loqt21 r-1ny4l3l" -testid="caret" ="" style="text-align: inherit; font-size: inherit; font-family: inherit; align-items: stretch; border-width: 0px; border-style: solid; border-color: black; display: flex; flex-basis: auto; flex-direction: column; flex-shrink: 0; list-style: none; margin: 0px; min-height: 20px; min-width: 0px; padding: 0px; : relative; : 0; overflow: ; justify-: center; cursor: pointer; outline-style: none; user-: none;"> New Hampshire reports an adult from Merrimack County with clade I mpox. It has become part of a new multi disease pandemic... Next steps in Mpox will be more new clades...more co-infections, more (aerosol/airborne) spread... Very likely measles/Mpox skin problems getting mixed up...a global big mess !
|
|
 |
|
|
Dutch Josh 2
Admin Group
Joined: 21 Aug 2024 Status: Online Points: 1783 |
Post Options
Thanks(0)
Quote Reply
Posted: 04 Mar 2025 at 8:12am |
|
https://flutrackers.com/forum/forum/africa-ac/monkeypox/1003943-drc-mpox-monkeypox-outbreak-2025?view=stream or https://flutrackers.com/forum/forum/africa-ac/monkeypox/1003943-drc-mpox-monkeypox-outbreak-2025?view=stream ;
Mpox in the DRC: a suspected case detected at N'djili international airport March 2, 2025 Kinshasa, March 2 , 2025 (ACP).- A suspected case of Mpox on an individual in his forties was isolated on Friday at N'djili international airport in Kinshasa, capital of the Democratic Republic of Congo (DRC), we learned on Sunday from a health source. " Last Friday, February 26, a user of the N'djili airport platform came to the airport health service because he had noticed the presence of skin rashes on his body. We screened (evaluated) the individual and noted the presence of skin rashes on the head, trunk, hands and soles of the feet, evolving for three days, with the notion of fever ," Dr. Claude Taty, head of the border hygiene post (PNHF) at N'djili international airport, told the ACP. A diagnosis of an Mpox alert was made, he indicated, before reporting that the health zone of the commune of N'sele was contacted and the individual assessed in the local hospital, Kinkole General Reference Hospital, the closest in the east of Kinshasa. " After investigation, the alert was validated, the sample was taken and the result came back positive for Mpox ," said the doctor, head of the PNHF station. According to him, the department was able to disinfect the premises where the patient had been received and a pre-list of contacts had been drawn up, with a view to monitoring by the surveillance team. To this end, the PNHF was able to share information with the Airways Authority (RVA), a public operator managing the country's airports, with the aim of strengthening epidemiological surveillance at N'djili international airport. Since July 2024, the date of the announcement of the Mpox epidemic in the Democratic Republic of Congo, 3 alerts had been raised in the N'djili airport platform, the most recent of which was a positive case, according to the doctor. A specialized service of the Ministry of Public Health, the PNHF is responsible for ensuring health controls at the borders of the Democratic Republic of Congo. ACP/CL DJ, More Mpox cases= more variants/mutations...some of them may be "better" in (aerosol/airborne) spreading... https://flutrackers.com/forum/forum/africa-ac/monkeypox/990497-south-africa-2024-2025-mpox?view=stream or https://flutrackers.com/forum/forum/africa-ac/monkeypox/990497-south-africa-2024-2025-mpox?view=stream ;Health Department Calls For Vigilance As Three New Mpox Cases Are Detected 28 February , 2025 The Department of Health would like to urge the public to take extra care as the country records three laboratory-confirmed cases of mpox. The first case was confirmed on 21 February in a 30-year-old male patient residing in Ekurhuleni, Gauteng Province with a recent travel history to Kampala, Uganda. The patient was diagnosed with Clade I mpox virus, which is currently circulating in the Democratic Republic of Congo and Uganda and has been reported in travellers returning to many locations around the globe. The other two cases, a 30-year-old male and a 27-year-old female, also from Ekurhuleni, were detected through contact tracing and monitoring conducted by outbreak response teams. This highlights the importance of information sharing by primary cases for contact tracing. All three cases are now recovering and self-isolating at home. This increases the total cumulative number of positive cases from 25 to 28 cases, including three deaths since the outbreak in May last year. These are the first positive cases of mpox recorded in South Africa this year, and the last case was recorded in September 2024. Globally, mpox continues to be a Public Health Emergency of International Concern (PHEIC) and Public Health Emergency of Continental Security (PHECS) as per the declarations by both the World Health Organization and Africa Centres for Disease Control and Prevention in August 2024. DJ, Only some/a lot of Mpox may be sex-related, quite a lot may show up in hotelworkers cleaning beds/baths... Mpox may be "out of the news"...only further worsening risks...
|
|
|
|
|
Dutch Josh 2
Admin Group
Joined: 21 Aug 2024 Status: Online Points: 1783 |
Post Options
Thanks(0)
Quote Reply
Posted: 08 Apr 2025 at 12:24pm |
|
https://afludiary.blogspot.com/2025/04/ukhsa-reports-case-of-mpox-clade-ib.html or https://afludiary.blogspot.com/2025/04/ukhsa-reports-case-of-mpox-clade-ib.html ;
UKHSA Reports A Case of Mpox Clade Ib Without Recent Travel or Known ExposureThree weeks ago the UKHSA announced that while - `Mpox remains a serious infection for some individuals and remains a World Health Organization (WHO) public health emergency of international concern (PHEIC)' - the Clade I Mpox No Longer Meets the Criteria of a High Consequence Infectious Disease (HCID) in the UK.
What sets this case apart is - all previously reported cases have had recent travel to endemic countries, or known exposure to someone who has - while this case has neither. - Whether this turns out to be a one-off event, or an early indication of community transmission, remains to be seen. Stay tuned. - https://en.wikipedia.org/wiki/2023%E2%80%932025_mpox_epidemic or https://en.wikipedia.org/wiki/2023%E2%80%932025_mpox_epidemic DJ. The 2023 variant showing up with no cleat history in the UK is "concerning"...
|
|
|
|
|
Dutch Josh 2
Admin Group
Joined: 21 Aug 2024 Status: Online Points: 1783 |
Post Options
Thanks(0)
Quote Reply
Posted: Yesterday at 5:19am |
|
https://www.globaltimes.cn/page/202504/1331734.shtml or https://www.globaltimes.cn/page/202504/1331734.shtml ;
China’s first monkeypox vaccine has entered phase I clinical trials at a hospital in Central China’s Henan Province and plans to recruit volunteers aged 18 and above in Zhengzhou, capital of the province.
The modified vaccinia virus Ankara (MVA)-based live attenuated monkeypox vaccine, independently developed by Shanghai Institute of Biological Products Co (SIBP) under China National Pharmaceutical Group Corporation, has received clinical trial approval from China’s National Medical Products Administration. The research team will conduct the phase I clinical trials at the Henan Infection Diseases Hospital in Zhengzhou, according to a statement from the SIBP. The trial plans to recruit 120 volunteers aged 18 and above, including 60 healthy individuals, 30 men who have sex with men, and 30 individuals living with HIV, according to the statement. Recruitment criteria specify that participants must have a body temperature below 37.3 C on the day of enrollment. Those who have been vaccinated with smallpox should be born before 1980. Male participants and women of childbearing age must have no plans to conceive within six months and must agree to use effective contraception for that duration. The application deadline is August 21, 2025. Previous reports noted that the vaccine received clinical trial approval from the National Medical Products Administration on September 9, 2024, making it the first monkeypox vaccine in China to be approved for clinical trials, The Paper reported. As a viral zoonotic disease caused by the monkeypox virus, monkeypox spreads through direct contact, respiratory droplets, secretions, contaminated objects, mother-to-child transmission and sexual contact. In the one- to five-day prodromal period, infected individuals may experience fever, chills, malaise, headache, back pain, sore throat, shortness of breath and swollen lymph nodes. Monkeypox shares clinical features with smallpox but presents milder symptoms and a lower mortality rate – between 1 percent to 10 percent. A distinguishing feature is lymphadenopathy (swollen lymph nodes). In August 2022, the World Health Organization issued interim guidance on monkeypox vaccination, recommending vaccination primarily for close contacts of monkeypox patients and high-risk groups exposed to the virus. High-risk groups include men who have sex with men, individuals with multiple sexual partners, healthcare workers, researchers, lab personnel handling monkeypox diagnostics, and outbreak response team members. The safety and efficacy of the MVA-based live attenuated monkeypox vaccine have been demonstrated through extensive clinical data. The vaccine is produced using a mature cell factory manufacturing process, which ensures stable manufacturing and reliable quality, experts said. Preclinical studies have confirmed its safety and its ability to provide strong immune protection against monkeypox virus challenges in non-human primate models, according to the statement from SIBP. As of now, no monkeypox vaccine has been approved for market use in China. There are currently two vaccines including JYNNEOS and ACAM2000 approved by the US Food and Drug Administration (US FDA) for the prevention of mpox and smallpox diseases in adults of 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. JYNNEOS is a live virus vaccine that contains MVA-Bavarian Nordic, a weakened, non-replicating orthopoxvirus. ACAM2000 is a live, replicating vaccinia virus vaccine, which can be shed from the vaccination site and can be spread to other parts of the body or to other people. Due to the risks of serious adverse reactions, ACAM2000 is not suitable for all populations, according to the US FDA. The JYNNEOS vaccine is marketed as Imvanex in the UK and Europe, and as Imvamune in Canada. All three versions contain the same MVA-based vaccine and are produced by the same manufacturer. Global Times |
|
|
|
|
Post Reply
|
Page <1 111213 |
| Tweet |
| Forum Jump | Forum Permissions You can post new topics in this forum You can reply to topics in this forum You cannot delete your posts in this forum You cannot edit your posts in this forum You can create polls in this forum You can vote in polls in this forum |
